Nelotanserin clinical trials
Also written APD125.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses nelotanserin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2015 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Axovant Sciences Ltd. (3) · Arena Pharmaceuticals (2)
Studies
Open first, then newest update. How each study uses nelotanserin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance InsomniaCompletedPhase 2Arena PharmaceuticalsNCT00664664Written as APD125
- Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)CompletedPhase 2Axovant Sciences Ltd.NCT02708186Written as Nelotanserin
- Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior DisorderTerminatedPhase 2Axovant Sciences Ltd.NCT02871427Written as Nelotanserin
- Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body DementiaCompletedPhase 2Axovant Sciences Ltd.NCT02640729Written as Nelotanserin
- Safety and Efficacy Study of APD125 in Patient With InsomniaCompletedPhase 2Arena PharmaceuticalsNCT00452179Written as APD125
Codes
What other systems call nelotanserin · ClinicalTrials.gg INT005561
- MeSH (NLM) C546600nelotanserinOne source NLM
- UNII (FDA) 4ZA73QEW2PNELOTANSERINConfirmed FDA, NLM, Wikidata
- Wikidata Q6990276nelotanserinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83996NelotanserinOne source FDA
- DrugBank DB12555One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546600 | nelotanserin | One source NLM |
| UNII (FDA) | 4ZA73QEW2P | NELOTANSERIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6990276 | nelotanserin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83996 | Nelotanserin | One source FDA |
| DrugBank | DB12555 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.